Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.49 - $9.63
Previous CloseN/A
Volume477.34K
Average Volume (3M)1.02M
Market Cap
$244.73M
Enterprise Value$256.10M
Total Cash (Recent Filing)$165.08M
Total Debt (Recent Filing)$32.19M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 08, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding92,849,500
10 Day Avg. Volume856,268
30 Day Avg. Volume1,017,968
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$17.67Price Target Upside342.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
COMPASS Pathways News
PremiumCompany Announcements
COMPASS Pathways Amends Executive Employment Agreements
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA $140M financing announced secures runway, funding both TRD and PTSD, while strategic collaborations with interventional psychiatry networks are laying the groundwork for commercial success.
Pipeline DevelopmentThe upcoming first P3 readout is anticipated, suggesting progress in the company's development pipeline.
Product PotentialCOMP360’s differentiated profile—demonstrated rapid efficacy, potential durability, and scalability versus SPRAVATO (esketamine)—positions it as a transformative treatment in treatment-resistant depression (TRD).
Bears Say
Market LimitationsOutstanding warrants exercisable on the release of the 26-week data from the COMP005 study have the potential to limit the stock's upside.
Regulatory ConcernsThe decision was influenced by the negative Lykos AdComm and CRL, raising concerns about trial design and management.
Stock DilutionThe stock price target has been adjusted from $23 to $15 primarily due to dilution from a recent offering.
---
Ownership Overview
22.14% Insiders
0.17% Mutual Funds
0.21% Other Institutional Investors
74.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.49 and its highest was $9.63 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $244.73M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Feb 27, 2025. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.626 by -$0.004.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.47.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 92,849,500 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.626. Following the earnings report the stock price went up 5.946%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
---
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (342.86% Upside)
$17.67 (342.86% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 373.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.74%
12-Months-Change
Fundamentals
Return on Equity
-81.56%
Trailing 12-Months
Asset Growth
-22.58%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
---
CMPS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights COMPASS Pathways' solid financial position and progress in clinical trials, particularly for TRD and PTSD, with strategic collaborations enhancing market insights. However, increased net loss and operational costs present financial challenges.Read More>---
CMPS Stock 12 Month Forecast
Average Price Target
$17.67
▲(342.86% Upside)
Technical Analysis
Best Analysts Covering CMPS
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-35.33%
reiterated a buy rating 3 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -35.33% per trade.
---